Toripalimab Plus Etoposide and Platinum-based Chemotherapy for Genitourinary Small Cell Carcinoma

PHASE2RecruitingINTERVENTIONAL
Enrollment

33

Participants

Timeline

Start Date

February 18, 2023

Primary Completion Date

February 18, 2025

Study Completion Date

February 18, 2026

Conditions
ToripalimabFirst-line Treatment
Interventions
DRUG

EP/EC+PD-1

Toripalimab 240 mg, administered on the first day of each cycle, and a cycle of administration every 3 weeks. Etoposide 100mg/m2, d1-3, cisplatin 25mg/m2, d1-3 or carboplatin AUC=5 d1, administered on the first day of each cycle, a cycle of administration every 3 weeks. Toripalimab combined with etoposide and cisplatin/carboplatin was used for 4 to 6 courses of treatment.

Trial Locations (1)

510060

RECRUITING

Sun Yat-sen University cancer center, Guangzhou

All Listed Sponsors
lead

Sun Yat-sen University

OTHER